Gut bugs may hold key to immunotherapy response in bladder cancer
NCT ID NCT04566029
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed pilot study looked at whether the proteins produced by gut bacteria differ between bladder cancer patients who respond to immunotherapy and those who do not. Researchers collected stool and blood samples from 40 patients with advanced bladder cancer. The goal was to find a protein signature that could predict treatment response, potentially personalizing therapy and reducing unnecessary side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which bladder cancer patients will benefit from immunotherapy, avoiding unnecessary side effects and costs for non-responders.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply to all patients. It is exploratory and does not test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Leon Berard
Lyon, 69373, France
-
HEGP GH Universitaire Paris Ouest
Paris, 75908, France
-
Hopital Tenon ( Paris)
Paris, Paris Cx 20, 75970, France
-
ICANS Strasbourg
Strasbourg, 67091, France
-
ICM parc euromedecine
Montpellier, Hérault, 34298, France
-
ICO-Site Paul Papin
Angers, 49055, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Sainte Cancerologie Lucien Neuwirth
Avignon, Saint Priest En Jarez, 42271, France
-
Iuct Oncopole
Toulouse, 31059, France